Untangling the multiple timescales of Alzheimer's disease

Integrating multiple biomarker and clinical measures can improve AD staging. Amyloid and tau PET clocks are straightforward and user-friendly tools for staging that have clear value, but they also have limitations in terms of their ability to consistently stage other disease-related measures across the full AD continuum. Next-generation amyloid and tau PET clocks could be derived based on more elaborate statistical models with more adequate regularization to avoid overfitting and the ability to include adjustments based on age and other readily available data.